- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06319820
En studie för att utvärdera TAR-210 kontra intravesikal cancerbehandling med enstaka medel hos deltagare med blåscancer (MoonRISe-1)
En fas 3, randomiserad studie som utvärderar effektiviteten och säkerheten av TAR-210 Erdafitinib intravesikalt tillförselssystem kontra intravesikal kemoterapi med enstaka medel hos deltagare med icke-muskelinvasiv blåscancer (IR-NMIBC) och känsliga FGFR-förändringar
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Study Contact
- Telefonnummer: 844-434-4210
- E-post: Participate-In-This-Study1@its.jnj.com
Studieorter
-
-
-
Buenos Aires, Argentina, C1419AHN
- Aktiv, inte rekryterande
- Hospital Sirio Libanes
-
Chabas, Argentina, C1425
- Aktiv, inte rekryterande
- Investigaciones Clinico Moleculares (ICM)
-
Córdoba, Argentina, 5000
- Aktiv, inte rekryterande
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
-
Córdoba, Argentina, X5000KPH
- Aktiv, inte rekryterande
- Centro Urologico Profesor Bengio
-
Mar del Plata, Argentina, B7602
- Aktiv, inte rekryterande
- Hospital Privado de la Comunidad
-
Rosario, Argentina, 2000
- Aktiv, inte rekryterande
- Sanatorio de la Mujer
-
-
-
-
-
Aalst, Belgien, 9300
- Rekrytering
- AZORG campus Aalst Moorselbaan
-
Brugge (Bruges), Belgien, 8000
- Rekrytering
- AZ Sint-Jan
-
Edegem, Belgien, 2650
- Avslutad
- UZ Antwerpen
-
Gent (Ghent), Belgien, 9000
- Rekrytering
- AZ Maria Middelares
-
Leuven, Belgien, 3000
- Aktiv, inte rekryterande
- Universitair Ziekenhuis Gasthuisberg
-
Sint-Niklaas, Belgien, 9100
- Rekrytering
- Vitaz
-
Yvoir, Belgien, 5530
- Rekrytering
- CHU UCL Namur - Site Godinne
-
-
-
-
-
Barretos, Brasilien, 14780-070
- Aktiv, inte rekryterande
- Fundacao Pio XII
-
Campinas, Brasilien, 13083-888
- Avslutad
- Universidade Estadual De Campinas
-
Natal, Brasilien, 59062 000
- Aktiv, inte rekryterande
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre, Brasilien, 90035-001
- Aktiv, inte rekryterande
- Hospital Moinhos de Vento
-
Porto Alegre, Brasilien, 90050 170
- Aktiv, inte rekryterande
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Salvador, Brasilien, 41810-011
- Aktiv, inte rekryterande
- HBA SA Assitencia Medica e Hospitalar
-
Santo André, Brasilien, 09060-650
- Aktiv, inte rekryterande
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
São Paulo, Brasilien, 01246-000
- Aktiv, inte rekryterande
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
São Paulo, Brasilien, 01509 900
- Avslutad
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brasilien, 01221-020
- Aktiv, inte rekryterande
- Irmandade Santa Casa de Misericordia de Sao Paulo
-
São Paulo, Brasilien, 01323 900
- Aktiv, inte rekryterande
- Real e Benemérita Associação Portuguesa de Beneficência
-
-
-
-
-
Aarhus, Danmark, 8200
- Rekrytering
- Aarhus University Hospital
-
Copenhagen, Danmark, 2100
- Rekrytering
- Rigshospitalet
-
Herlev, Danmark, 2730
- Rekrytering
- Herlev Hospital
-
Odense, Danmark, 5000
- Rekrytering
- Odense Universitetshospital
-
Roskilde, Danmark, 4000
- Rekrytering
- Zealand University Hospital
-
-
-
-
-
Lille, Frankrike, 59000
- Avslutad
- Hospital Center University De Lille
-
Limoges, Frankrike, 87000
- Rekrytering
- Polyclinique de Limoges - Francois Chenieux
-
Lyon, Frankrike, 69003
- Rekrytering
- Hôpital Edouard Herriot
-
Marseille, Frankrike, 13009
- Rekrytering
- Institut Paoli Calmettes
-
Paris, Frankrike, 75010
- Rekrytering
- Hopital Saint Louis
-
Paris, Frankrike, 75013
- Rekrytering
- CHU Pitie Salpetriere
-
Paris, Frankrike, 75018
- Rekrytering
- APHP - Hopital Bichat - Claude Bernard
-
Quint-Fonsegrives, Frankrike, 31130
- Rekrytering
- Clinique de la Croix du Sud
-
Rennes, Frankrike, 35000
- Avslutad
- Chu Rennes Hopital Pontchaillou
-
Toulouse, Frankrike, 31059
- Rekrytering
- CHU Rangueil
-
Villejuif, Frankrike, 94805
- Rekrytering
- Institut Gustave Roussy
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72211
- Avslutad
- Arkansas Urology
-
-
California
-
Los Alamitos, California, Förenta staterna, 90720
- Aktiv, inte rekryterande
- Genesis Research LLC
-
Los Angeles, California, Förenta staterna, 90033
- Aktiv, inte rekryterande
- USC Norris Comprehensive Cancer Center
-
Orange, California, Förenta staterna, 92868
- Aktiv, inte rekryterande
- University of California Irvine Medical Center
-
San Diego, California, Förenta staterna, 92123
- Aktiv, inte rekryterande
- Om Research LLC
-
Sherman Oaks, California, Förenta staterna, 91411
- Avslutad
- Genesis Research LLC 1
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- Avslutad
- University of Colorado Cancer Center Anschultz Cancer Pavilion
-
Lakewood, Colorado, Förenta staterna, 80228
- Aktiv, inte rekryterande
- Colorado Clinical Research
-
San Luis, Colorado, Förenta staterna, 63141
- Avslutad
- Mercy Research
-
San Luis, Colorado, Förenta staterna, 63141
- Aktiv, inte rekryterande
- Specialty Clinical Research of St Louis
-
-
Florida
-
Tampa, Florida, Förenta staterna, 33612
- Aktiv, inte rekryterande
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Avslutad
- Northwestern University
-
-
Indiana
-
Jeffersonville, Indiana, Förenta staterna, 47130
- Avslutad
- First Urology
-
-
Kansas
-
Wichita, Kansas, Förenta staterna, 67226
- Aktiv, inte rekryterande
- Wichita Urology Group
-
-
Louisiana
-
New Orleans, Louisiana, Förenta staterna, 70121-2429
- Aktiv, inte rekryterande
- Ochsner Health System
-
-
Maryland
-
Hanover, Maryland, Förenta staterna, 21076
- Avslutad
- Chesapeake Urology Research Associates
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Avslutad
- Brigham And Women's Hospital
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48201
- Aktiv, inte rekryterande
- Karmanos Cancer Institute
-
Royal Oak, Michigan, Förenta staterna, 48073
- Aktiv, inte rekryterande
- Comprehensive Urology
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68114
- Aktiv, inte rekryterande
- The Urology Center, PC
-
-
New Jersey
-
New Brunswick, New Jersey, Förenta staterna, 08901
- Aktiv, inte rekryterande
- Cancer Institute Of New Jersey
-
-
New York
-
New York, New York, Förenta staterna, 10065
- Aktiv, inte rekryterande
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Förenta staterna, 10016
- Avslutad
- Integrated Medical Professionals
-
Syracuse, New York, Förenta staterna, 13210
- Aktiv, inte rekryterande
- SUNY Upstate Med Univ
-
Syracuse, New York, Förenta staterna, 13210
- Aktiv, inte rekryterande
- Associated Medical Professionals of Ny
-
-
North Carolina
-
Charlotte, North Carolina, Förenta staterna, 28204
- Aktiv, inte rekryterande
- Levine Cancer Institute
-
Raleigh, North Carolina, Förenta staterna, 27612
- Aktiv, inte rekryterande
- Associated Urologists of North Carolina
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Förenta staterna, 19004
- Avslutad
- MidLantic Urology
-
Lancaster, Pennsylvania, Förenta staterna, 17604
- Aktiv, inte rekryterande
- Keystone Urology Specialists
-
-
South Carolina
-
Myrtle Beach, South Carolina, Förenta staterna, 29572
- Aktiv, inte rekryterande
- Carolina Urologic Research Center
-
-
Tennessee
-
Germantown, Tennessee, Förenta staterna, 38138
- Aktiv, inte rekryterande
- The Conrad Pearson Clinic
-
Knoxville, Tennessee, Förenta staterna, 37920
- Avslutad
- University of Tennessee Medical Center
-
Nashville, Tennessee, Förenta staterna, 37209
- Aktiv, inte rekryterande
- Urology Associates
-
-
Texas
-
Austin, Texas, Förenta staterna, 78745
- Aktiv, inte rekryterande
- Urology Austin
-
Dallas, Texas, Förenta staterna, 75231
- Aktiv, inte rekryterande
- Urology Clinics of North Texas
-
Dallas, Texas, Förenta staterna, 75390
- Avslutad
- UT Southwestern
-
Houston, Texas, Förenta staterna, 77027
- Aktiv, inte rekryterande
- Houston Metro Urology
-
-
Washington
-
Spokane, Washington, Förenta staterna, 99202
- Aktiv, inte rekryterande
- Spokane Urology
-
-
-
-
-
Hong Kong, Hong Kong
- Aktiv, inte rekryterande
- Queen Mary Hospital
-
Hong Kong, Hong Kong
- Aktiv, inte rekryterande
- Prince Of Wales Hospital
-
-
-
-
-
Cork, Irland, T12 DC4A
- Aktiv, inte rekryterande
- Cork University Hospital
-
Dublin, Irland, D07 A8NN
- Aktiv, inte rekryterande
- Mater Misericordiae University Hospital
-
Dublin, Irland, D07 WKW8
- Aktiv, inte rekryterande
- Mater Private Hospital
-
Dublin, Irland, D24 NR0A
- Aktiv, inte rekryterande
- Adelaide and Meath Hospital
-
-
-
-
-
Haifa, Israel, 3109601
- Rekrytering
- Rambam Health Care Campus
-
Ramat Gan, Israel, 52621
- Rekrytering
- Sheba Medical Center
-
Sderot, Israel, 13100
- Rekrytering
- Ziv Medical Center
-
Tel Aviv, Israel, 6423906
- Rekrytering
- Sourasky Medical Center
-
Yeruham, Israel, 9112001
- Avslutad
- Hadassah University Hospita Ein Kerem
-
-
-
-
-
Arezzo, Italien, 52100
- Rekrytering
- Ospedale S. Donato Arezzo, USL 8 - U.O. Oncologia Medica
-
Bergamo, Italien, 24125
- Rekrytering
- Cliniche Humanitas Gavazzeni
-
Brescia, Italien, 25123
- Rekrytering
- ASST Spedali Civili Brescia
-
Milan, Italien, 20133
- Rekrytering
- Istituto Dei Tumori Di Milano
-
Milan, Italien, 20132
- Avslutad
- Ospedale San Raffaele
-
Romagnano, Italien, 00128
- Rekrytering
- Universita Campus Bio-Medico di Roma
-
Romagnano, Italien, 00144
- Rekrytering
- Istituto Nazionale Tumori Regina Elena
-
Rozzano, Italien, 20089
- Rekrytering
- Istituto Clinico Humanitas
-
Torino, Italien, 10126
- Rekrytering
- A.O.Citta della Salute e della Scienza di Torino
-
-
-
-
-
Amagasaki, Japan, 660 8550
- Aktiv, inte rekryterande
- Hyogo Prefectural Amagasaki General Medical Center
-
Kawasaki, Japan, 216 8511
- Rekrytering
- St Marianna University Hospital
-
Kobe, Japan, 650 0047
- Aktiv, inte rekryterande
- Kobe City Medical Center General Hospital
-
Kumamoto, Japan, 860 0008
- Aktiv, inte rekryterande
- National Hospital Organization Kumamoto Medical Center
-
Osaka, Japan, 541 8567
- Rekrytering
- Osaka International Cancer Institute
-
Saitama, Japan, 350 8550
- Aktiv, inte rekryterande
- Saitama Medical Center
-
Wakayama, Japan, 640 8558
- Aktiv, inte rekryterande
- JRC Wakayama Medical Center
-
Yokohama, Japan, 221 0855
- Rekrytering
- Yokohama Municipal Citizen's Hospital
-
Yokohama, Japan, 232 0024
- Aktiv, inte rekryterande
- Yokohama City University Medical Center
-
Yokosuka, Japan, 238 8558
- Rekrytering
- Yokosuka Kyosai Hospital
-
Ōta-ku, Japan
- Rekrytering
- Gunma Prefectural Cancer Center
-
-
-
-
-
Beijing, Kina, 100191
- Aktiv, inte rekryterande
- Peking University Third Hospital
-
Beijing, Kina, 100050
- Aktiv, inte rekryterande
- Beijing Friendship Hospital Capital Medical University
-
Changsha, Kina, 410013
- Aktiv, inte rekryterande
- Hunan Cancer hospital
-
Chengdu, Kina, 610041
- Aktiv, inte rekryterande
- West China School of Medicine/West China Hospital, Sichuan University
-
Chengdu, Kina, 610014
- Aktiv, inte rekryterande
- The Third People's Hospital of Chengdu
-
Chongqing, Kina, 400033
- Aktiv, inte rekryterande
- Chongqing Cancer Hospital
-
Fuzhou, Kina, 350001
- Aktiv, inte rekryterande
- Fujian Medical University Union Hospital
-
Guangzhou, Kina, 510060
- Aktiv, inte rekryterande
- Sun Yat Sen University Cancer Center
-
Nanjing, Kina, 210008
- Aktiv, inte rekryterande
- Nanjing Drum Tower Hospital
-
Nanjing, Kina, 210009
- Aktiv, inte rekryterande
- Zhongda Hospital Southeast University
-
Shanghai, Kina, 200031
- Aktiv, inte rekryterande
- Huadong Hospital Affiliated to Fudan University
-
Tianjin, Kina, 300061
- Aktiv, inte rekryterande
- The Second Hospital Of Tianjin Medical University
-
Wenzhou, Kina, 325000
- Aktiv, inte rekryterande
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Kina, 430032
- Aktiv, inte rekryterande
- Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology
-
Xinshi, Kina, 710063
- Aktiv, inte rekryterande
- The First Affiliated Hospital of Xian Jiaotong University
-
Xuzhou, Kina, 221004
- Aktiv, inte rekryterande
- The Affiliated Hospital of Xuzhou Medical University
-
Ürümqi, Kina, 830011
- Aktiv, inte rekryterande
- Cancer Hospital of Xinjiang Medical University
-
-
-
-
-
Bialystok, Polen, 15 276
- Aktiv, inte rekryterande
- Uniwersytecki Szpital Kliniczny w Bialymstoku
-
Bydgoszcz, Polen, 85 048
- Aktiv, inte rekryterande
- IN VIVO Sp. z o.o
-
Bydgoszcz, Polen, 85 796
- Avslutad
- Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy
-
Lublin, Polen, 20 090
- Aktiv, inte rekryterande
- Uniwersytecki Szpital Kliniczny nr 4
-
Przemyśl, Polen, 37 700
- Aktiv, inte rekryterande
- Wojewodzki Szpital im Sw Ojca Pio w Przemyslu
-
Tarnów, Polen, 33-100
- Aktiv, inte rekryterande
- Szpital Wojewodzki Im Sw Lukasza Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Tarnowie
-
Torun, Polen, 87-100
- Avslutad
- Medicover Integrated Clinical Services Sp z o o
-
Wiele, Polen, 05-135
- Aktiv, inte rekryterande
- Mazowiecki Szpital Onkologiczny Sp z o o
-
Wroclaw, Polen, 50 981
- Avslutad
- 4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu
-
Wroclaw, Polen, 53-413
- Aktiv, inte rekryterande
- Dolnoslaskie Centrum Onkologii Pulmonologii i Hematologii
-
-
-
-
-
Alzira, Spanien, 46600
- Rekrytering
- Hosp. Univ. de La Ribera
-
Barcelona, Spanien, 08025
- Rekrytering
- Fund. Puigvert
-
Barcelona, Spanien, 08036
- Rekrytering
- Hosp Clinic de Barcelona
-
Barcelona, Spanien, 08035
- Avslutad
- Hosp Univ Vall D Hebron
-
Cadiz, Spanien, 11009
- Rekrytering
- Hosp. Puerta Del Mar
-
Castillón, Spanien, 12004
- Rekrytering
- Hosp. Gral. Univ. de Castellon
-
Jerez de la Frontera, Spanien, 11407
- Rekrytering
- Hosp. de Jerez de La Frontera
-
La Coruña (A Coruña), Spanien, 15006
- Rekrytering
- Hosp Univ A Coruna
-
Madrid, Spanien, 28041
- Rekrytering
- Hosp. Univ. 12 de Octubre
-
Madrid, Spanien, 28027
- Rekrytering
- Clinica Univ. de Navarra
-
Madrid, Spanien, 28007
- Avslutad
- Hosp. Gral. Univ. Gregorio Maranon
-
Málaga, Spanien, 29010
- Rekrytering
- Hosp Virgen de La Victoria
-
Oviedo, Spanien, 33011
- Avslutad
- Hosp. Univ. Central de Asturias
-
Sabadell, Spanien, 08208
- Rekrytering
- Hosp.Univ.Parc Tauli
-
Seville, Spanien, 41013
- Avslutad
- Hosp. Virgen Del Rocio
-
Valencia, Spanien, 46010
- Rekrytering
- Hosp. Clinico Univ. de Valencia
-
-
-
-
-
Bristol, Storbritannien, BS105NB
- Aktiv, inte rekryterande
- Southmead Hospital
-
London, Storbritannien, W6 8RF
- Aktiv, inte rekryterande
- Charing Cross Hospital
-
London, Storbritannien, EC1A 7BE
- Aktiv, inte rekryterande
- St Bartholomews Hospital
-
Newcastle upon Tyne, Storbritannien, NE7 7DN
- Aktiv, inte rekryterande
- Newcastle Freeman Hospital
-
Sheffield, Storbritannien, S10 2SJ
- Aktiv, inte rekryterande
- Sheffield Teaching Hospitals NHS Foundation Trust
-
Southampton, Storbritannien, SO16 6YD
- Aktiv, inte rekryterande
- Southampton General Hospital
-
Sutton, Storbritannien, SM2 5PT
- Aktiv, inte rekryterande
- Royal Marsden Hospital
-
-
-
-
-
Chuncheon, Sydkorea, 28644
- Avslutad
- Chungbuk National University Hospital
-
Gyeongin, Sydkorea, 10408
- Rekrytering
- National Cancer Center
-
Sangam-dong, Sydkorea, 58128
- Rekrytering
- Chonnam National University Hwasun Hospital
-
Seoul, Sydkorea, 06351
- Rekrytering
- Samsung Medical Center
-
Seoul, Sydkorea, 3080
- Rekrytering
- Seoul National University Hospital
-
Seoul, Sydkorea, 06591
- Aktiv, inte rekryterande
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Hradec Králové, Tjeckien, 500 05
- Avslutad
- Fakultni nemocnice Hradec Kralove
-
Olomouc, Tjeckien, 779 00
- Rekrytering
- Fakultni nemocnice Olomouc
-
Prague, Tjeckien, 128 08
- Rekrytering
- Vseobecna fakultni nemocnice v Praze
-
Prague, Tjeckien, 150 06
- Rekrytering
- Fakultni nemocnice v Motole
-
Prague, Tjeckien, 140 59
- Rekrytering
- Fakultni Thomayerova nemocnice
-
-
-
-
-
?zmir, Turkiet (Türkiye), 35330
- Rekrytering
- Dokuz Eylul University Medical Faculty
-
Adana, Turkiet (Türkiye), 01120
- Avslutad
- Adana Baskent Practice and Research Hospital
-
Ankara, Turkiet (Türkiye), 06200
- Rekrytering
- Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
Ankara, Turkiet (Türkiye), 06100
- Avslutad
- Ankara University Medical Faculty
-
Istanbul, Turkiet (Türkiye), 34722
- Rekrytering
- T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
-
Istanbul, Turkiet (Türkiye), 34153
- Avslutad
- Istanbul University Cerrahpasa Medical Faculty
-
Istanbul, Turkiet (Türkiye), 34865
- Rekrytering
- Kartal Dr Lutfi Kirdar sehir Hastanesi
-
-
-
-
-
Berlin, Tyskland, 10117
- Aktiv, inte rekryterande
- Charite - Universitaetsmedizin Berlin (CCM)
-
Braunschweig, Tyskland, 38126
- Rekrytering
- Stadtisches Klinikum Braunschweig gGmbH-Klinik fur Urologie und Uroonkologie
-
Cologne, Tyskland, 50968
- Rekrytering
- Studienzentrum Bayenthal
-
Dresden, Tyskland, 01307
- Avslutad
- Urologische Gemeinschaftspraxis
-
Frankfurt am Main, Tyskland, 60596
- Rekrytering
- Universitaetsklinikum Frankfurt
-
Hamburg, Tyskland, 22081
- Aktiv, inte rekryterande
- Urologikum Hamburg MVZ - Germany
-
Herne, Tyskland, 44625
- Rekrytering
- Marien hospital Herne
-
Jena, Tyskland, 07747
- Aktiv, inte rekryterande
- Universitatsklinikum Jena
-
München, Tyskland, 81675
- Avslutad
- Klinikum rechts der Isar an der Technischen Universitat Munchen
-
Straubing, Tyskland, 94315
- Rekrytering
- Klinikum St. Elisabeth Straubing GmbH
-
Stuttgart, Tyskland, 70174
- Avslutad
- Katharinenhospital Innere Medizin
-
-
-
-
-
Graz, Österrike, 8036
- Rekrytering
- Medizinische Universitaet Graz
-
Innsbruck, Österrike, 6020
- Rekrytering
- Medizinische Universitat Innsbruck
-
Leopoldsdorf (Wien), Österrike, 1090
- Rekrytering
- Medical University Vienna MUV
-
Linz, Österrike, 4020
- Rekrytering
- Ordensklinikum Linz GmbH Elisabethinen
-
Salzburg, Österrike, 5020
- Rekrytering
- Universitaetsklinikum Salzburg Landeskrankenhaus
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Main study only: Have a histologically confirmed diagnosis (within 90 days of randomization) of IR-NMIBC with at least one of the following criteria fulfilled: a. Ta low grade (LG)/ Grade 1 (G1): primary or recurrent, b. Ta LG/G2: primary or recurrent and c. Greater than or equal to (>=) 1 of the following risk factors: i. Multiple Ta LG tumors, ii. Solitary LG tumor >= 3 cm, iii. Early recurrence (less than [<] 1 year), iv. Frequent recurrence (greater than [>] 1 per year), v. Recurrence after prior adjuvant intravesical treatment (single perioperative dose of chemotherapy does not fulfill this risk factor)
- Substudy only: Have a histologically confirmed new diagnosis (within 90 days of randomization) of IR-NMIBC for whom MMC is deemed the therapy of choice according to local standard of care with at least 1 of the following criteria fulfilled: a. Ta LG/G1, b. Ta LG/G2, and >=1 of the following risk factors: i) Multiple Ta LG tumors, ii) Solitary LG tumor >=3 cm
- Have a susceptible fibroblast growth factor receptor (FGFR) mutation or fusion either by urine testing or tumor tissue testing (from TURBT tissue), as determined by central or local testing
- Participants must be willing to undergo all study procedures (e.g., multiple cystoscopies from Screening through the end of study and TURBT for assessment of recurrence/progression) and receive the assigned treatment, including intravesical chemotherapy if randomized into that arm.
- Visible papillary disease must be fully resected prior to randomization and absence of disease must be documented at Screening cystoscopy
- Can have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment
- Have an Eastern Cooperative Oncology Group performance status of 0 to 2
Exclusion Criteria:
- Known allergies, hypersensitivity, or intolerance to any study component or its excipients, including: a. Erdafitinib excipients; b.TAR-210 drug delivery system constituent materials ; c. urinary placement catheter materials; d. MMC or chemically related drugs; e. Gemcitabine or chemically related drugs
- Presence of any bladder or urethral anatomic feature (that is, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-210 or passage of a urethral catheter for intravesical chemotherapy
- Polyuria with recorded 24-hour urine volumes > 4000 milliliters (mL)
- Current indwelling urinary catheters, however, intermittent catheterization is acceptable
- Had major surgery or had significant traumatic injury and/or not fully recovered within 4 weeks before first dose (TURBT is not considered major surgery)
Substudy:
- Previous diagnosis of histologically confirmed urothelial bladder carcinoma at any time prior to current qualifying diagnosis
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Main Study: Group A: TAR-210
Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year. |
TAR-210 will be administered intravesically.
Andra namn:
|
|
Aktiv komparator: Main Study: Group B: MMC or Gemcitabine
Participants in Group B will receive intravesical mitomycin C (MMC) or gemcitabine (investigator's choice) once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 months and up to 1 year. |
Gemcitabine will be administered intravesically. MMC will be administered intravesically. |
|
Experimentell: Substudy: Group A: TAR-210
Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year. |
TAR-210 will be administered intravesically.
Andra namn:
|
|
Aktiv komparator: Substudy: Group B: MMC
Participants in substudy Group B will receive intravesical MMC once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 months and up to 1 year. |
MMC will be administered intravesically. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Disease Free Survival (DFS)
Tidsram: From randomization to the date of the first documented recurrence, disease progression or death (approximately 4 years and 2 months)
|
DFS is measured as the time from randomization to the date of the first documented recurrence of Ta non-muscle invasive bladder cancer (NMIBC) of any grade, disease progression, or death due to any cause, whichever occurs first. |
From randomization to the date of the first documented recurrence, disease progression or death (approximately 4 years and 2 months)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Time to next Treatment (TTNT)
Tidsram: From randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer (approximately 4 years and 2 months)
|
TTNT is measured as the time from randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer. |
From randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer (approximately 4 years and 2 months)
|
|
High Grade Recurrence-free Survival (HG RFS)
Tidsram: From randomization to the date of first documented evidence of HG NMIBC or death (approximately 4 years and 2 months)
|
HG RFS is measured as the time from randomization to the date of first documented evidence of HG NMIBC or death, whichever occurs first |
From randomization to the date of first documented evidence of HG NMIBC or death (approximately 4 years and 2 months)
|
|
Progression Free Survival (PFS)
Tidsram: From randomization to the date of first documented disease progression or death (approximately 4 years and 2 months)
|
PFS is measured as the time from randomization to the date of first documented evidence of disease progression or death, whichever occurs first. |
From randomization to the date of first documented disease progression or death (approximately 4 years and 2 months)
|
|
Number of Diagnostic and Therapeutic Invasive Urological Interventions after Study Treatment
Tidsram: From study treatment completion up to trial discontinuation (approximately 4 years and 2 months)
|
Number of diagnostic and therapeutic invasive urological interventions after study treatment, that is, endoscopic procedures (e.g., cystoscopies, transurethral resection of bladder tumors (TURBTs), ureteroscopies, urethral interventions, urethral stricture/bladder neck incision), catheterization (intravesical, suprapubic), intravesical treatments, major surgeries (e.g., radical cystectomy, simple cystectomy, urethroplasty) will be reported. |
From study treatment completion up to trial discontinuation (approximately 4 years and 2 months)
|
|
Number of Participants With Adverse Events (Including Physical Examination, Vital Signs and Laboratory Abnormalities)
Tidsram: From first dose up to 30 days after last dose of study treatment (approximately 4 years and 2 months)
|
An AE is any untoward medical occurrence in a participant participating in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product, that does not necessarily have a causal relationship with the treatment. AEs will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Severity of AEs has 5 grades based on CTCAE criteria: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening and Grade 5: Death. Number of participants with adverse events (including physical examination, vital signs and laboratory abnormalities) will be reported. |
From first dose up to 30 days after last dose of study treatment (approximately 4 years and 2 months)
|
|
Overall Survival (OS)
Tidsram: From randomization to the date of death (approximately 4 years and 2 months)
|
OS is defined as the time from randomization to the date of death from any cause. |
From randomization to the date of death (approximately 4 years and 2 months)
|
|
European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire Core-30 items (EORTC-QLQ-C30) Scores
Tidsram: Baseline, Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. It incorporates 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scales (fatigue, pain, and nausea or vomiting), and a global health status or HRQoL scale. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Baseline, Weeks 6, 12, 24, 36, and 48
|
|
European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire for Non muscle Invasive Bladder Cancer (EORTC-QLQ-NMIBC24) Scores
Tidsram: Baseline, Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Baseline, Weeks 6, 12, 24, 36, and 48
|
|
Percentage of Participants With Significant Change From Baseline in EORTC-QLQ-C30 Scores
Tidsram: Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-C30 is a core 30-item questionnaire for evaluating the HRQoL of participants participating in cancer clinical studies. It incorporates 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scales (fatigue, pain, and nausea or vomiting), and a global health status or HRQoL scale. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Weeks 6, 12, 24, 36, and 48
|
|
Percentage of Participants With Significant Change From Baseline in EORTC-QLQ-NMIBC24 Scores
Tidsram: Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Weeks 6, 12, 24, 36, and 48
|
Samarbetspartners och utredare
Utredare
- Studierektor: Johnson & Johnson Enterprise Innovation Inc. Clinical Trial, Johnson & Johnson Enterprise Innovation Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Manliga urogenitala sjukdomar
- Urologiska sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Neoplasmer efter histologisk typ
- Neoplasmer, körtel och epitel
- Urologiska neoplasmer
- Carcinom
- Sjukdomar i urinblåsan
- Neoplasmer i urinblåsan
- Icke-muskelinvasiva blåsneoplasmer
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Deoxycytidin
- Cytidin
- Pyrimidin nukleosider
- Pyrimidiner
- Gemcitabin
- erdafitinib
Andra studie-ID-nummer
- 42756493BLC3004
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .